Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does FOSCARNET Cause Malignant neoplasm progression? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Malignant neoplasm progression have been filed in association with FOSCARNET (Foscarnet Sodium). This represents 0.5% of all adverse event reports for FOSCARNET.

10
Reports of Malignant neoplasm progression with FOSCARNET
0.5%
of all FOSCARNET reports
10
Deaths
1
Hospitalizations

How Dangerous Is Malignant neoplasm progression From FOSCARNET?

Of the 10 reports, 10 (100.0%) resulted in death, 1 (10.0%) required hospitalization, and 1 (10.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for FOSCARNET. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does FOSCARNET Cause?

Off label use (610) Drug ineffective (368) Drug resistance (309) Acute kidney injury (246) Cytomegalovirus infection (200) Nephropathy toxic (198) Pathogen resistance (190) Renal impairment (184) Pancytopenia (170) Cytomegalovirus infection reactivation (167)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which FOSCARNET Alternatives Have Lower Malignant neoplasm progression Risk?

FOSCARNET vs FOSFOMYCIN FOSCARNET vs FOSFOMYCIN TROMETHAMINE FOSCARNET vs FOSINOPRIL FOSCARNET vs FOSPHENYTOIN FOSCARNET vs FOSTAMATINIB

Related Pages

FOSCARNET Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression FOSCARNET Demographics